Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-3-28
pubmed:abstractText
In humans, initial events of pancreatic carcinogenesis remain unknown, and the question of whether this cancer, which has a ductal phenotype, exclusively arises from duct cells has been raised. Previous studies have demonstrated that transgenic expression of the CCK2 receptor in acinar cells of ElasCCK2 mice plays a role in the development of pancreatic neoplasia. The aim of our study was to examine initial steps of carcinogenesis in ElasCCK2 mice, adding a supplementary defect by using a chemical carcinogen, azaserine. Results of posttreatment sequential immunohistochemical examinations and quantifications demonstrate that mice responded to azaserine. Transition of acinar cells into duct-like cells expressing Pdx1 and gastrin, as well as proliferation of acinar cells, were transiently observed in both transgenic and control mice. The carcinogen also induced formation of preneoplastic lesions, adenomas, exhibiting properties of autonomous growth. Importantly, expression of the CCK2 receptor increased the susceptibility of pancreas to azaserine. Indeed, treated ElasCCK2 mice exhibited larger areas of pancreatic acinar-ductal transition, increased cellular proliferation as well as larger adenomas areas vs. control mice. These amplified responses may be related to auto/paracrine stimulation of CCK2 receptor by gastrin expressed in newly formed duct-like cells. Our results demonstrate that activation of CCK2 receptor and azaserine result in cumulative effects to favor the emergence of a risk situation that is a potential site for initiation of carcinogenesis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0020-7136
pubmed:author
pubmed:copyrightInfo
(c) 2005 Wiley-Liss, Inc.
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
115
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
46-54
pubmed:dateRevised
2011-6-1
pubmed:meshHeading
pubmed-meshheading:15688412-Adenoma, pubmed-meshheading:15688412-Animals, pubmed-meshheading:15688412-Antimetabolites, Antineoplastic, pubmed-meshheading:15688412-Azaserine, pubmed-meshheading:15688412-Bromodeoxyuridine, pubmed-meshheading:15688412-Carcinogens, pubmed-meshheading:15688412-Carcinoma, Acinar Cell, pubmed-meshheading:15688412-Cell Proliferation, pubmed-meshheading:15688412-Coloring Agents, pubmed-meshheading:15688412-Homeodomain Proteins, pubmed-meshheading:15688412-Homozygote, pubmed-meshheading:15688412-Immunohistochemistry, pubmed-meshheading:15688412-Inflammation, pubmed-meshheading:15688412-Lymphocytes, pubmed-meshheading:15688412-Mice, pubmed-meshheading:15688412-Mice, Transgenic, pubmed-meshheading:15688412-Pancreatic Neoplasms, pubmed-meshheading:15688412-Phenotype, pubmed-meshheading:15688412-Precancerous Conditions, pubmed-meshheading:15688412-Receptor, Cholecystokinin B, pubmed-meshheading:15688412-Receptors, G-Protein-Coupled, pubmed-meshheading:15688412-Risk, pubmed-meshheading:15688412-Time Factors, pubmed-meshheading:15688412-Trans-Activators, pubmed-meshheading:15688412-Transgenes
pubmed:year
2005
pubmed:articleTitle
Transgenic expression of CCK2 receptors sensitizes murine pancreatic acinar cells to carcinogen-induced preneoplastic lesions formation.
pubmed:affiliation
INSERM U531, IFR31, Hospital Rangueil, Toulouse, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't